Drs. Ashkan Abbey and Ehsan Rahimy join host Dr. Jay Sridhar to discuss recent developments in the medical retina and injectable space, including faricimab versus high-dose aflibercept, biosimilars for ranibizumab and aflibercept, off-label bevacaziumb shortages, dry age-related macular degeneration (AMD) therapies, private equity acquisitions, and the new drug pipeline.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.